Efficacy and Safety Of a New Olopatadine Hydrochloride, 0.77% Ophthalmic Formulation In Patients With Allergic Conjunctivitis Using The Conjunctival Allergen Challenge (CAC) Model (NCT01479374)

被引：0

作者：

Torkildsen, Gail ^{[1
]}

Macejko, Thomas ^{[2
]}

Narvekar, Abhijit ^{[3
]}

Bergmann, Mark ^{[4
]}

机构：

[1] Andover Eye Associates, Andover, MA USA

[2] Apex Eye, Fairfield, OH USA

[3] Alcon Labs Inc, Ft Worth, TX 76101 USA

[4] Apex Eye, Cincinnati, OH USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2014年 / 133卷 / 02期

关键词：

D O I：

10.1016/j.jaci.2013.12.982

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

957

引用

页码：AB277 / AB277

页数：1

共 30 条

[21] Treatment of Chronic Allergic Conjunctivitis with Sustained Release Dexamethasone Using a Modified Conjunctival Allergen Challenge (Ora-CAC®) Model
Mulani, Deepa
McLaurin, Eugene B.
Repke, Carolyn
Sato, Michelle
Gomes, Paul J.
Ankerud, Eric
Bassett, Michael
Blizzard, Charles D.
Driscoll, Arthur
Sawhney, Amar
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
[22] Evaluating Sustained Release Dexamethasone for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge (Ora-CAC®) Model
Bassett, Michael
Mulani, Deepa
Blizzard, Charles D.
Driscoll, Arthur
Sawhney, Amar
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
[23] Olopatadine Hydrochloride Ophthalmic Solution 0.7% is Superior to Fluticasone Propionate Nasal Spray 50 mcg or Loratadine in Preventing Signs and Symptoms of Allergic Conjunctivitis using an Allergen Challenge Model
Gomes, Paul
Jones, Stephanie
Quealy, Kara
Chin, T.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[24] Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
Meier, Edward J.
Torkildsen, Gail L.
Gomes, Paul J.
Jasek, Mark C.
CLINICAL OPHTHALMOLOGY, 2018, 12 : 2617 - 2628
[25] Bepotastine Besilate Ophthalmic Solution 1.5% Produces Strong Clinical Benefit for Ocular Itching Immediately Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Clark, J. C.
Williams, J. I.
Gomes, P. J.
Abelson, M. B.
Gow, J. A.
McNamara, T. R.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB256 - AB256
[26] TREATMENT OF OCULAR ITCHING WITH BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% FOR SUBJECTS WITH MORE SEVERE ITCHING RESPONSE IN A CONJUNCTIVAL ALLERGEN CHALLENGE (CAC) CLINICAL MODEL OF ALLERGIC CONJUNCTIVITIS
Kennedy, K. S.
Williams, J. I.
Gow, J. A.
Abelson, M. B.
McNamara, T. R.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (05) : A129 - A129
[27] Rhinorrhea Reduction Using BepreveTm Ophthalmic Solution 1.5% in a Clinical Model of Allergic Conjunctivitis: An Analysis of Pooled Data From Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials
Gow, J. A.
Williams, J. I.
Gomes, P. J.
Abelson, M. B.
McNamara, T. R.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
[28] Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom (NOCS) Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Gow, J. A.
Macejko, T. T.
Bergmann, M. T.
Meier, E.
Abelson, M. B.
Williams, J. I.
McNamara, T. R.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB255 - AB255
[29] BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% PROVIDES A RAPID AND SUSTAINED REDUCTION IN OCULAR ITCH FOR SEVERELY ALLERGIC SUBJECTS FOLLOWING EXPOSURE TO RAGWEED OR GRASS POLLENS USING THE CONJUNCTIVAL ALLERGEN CHALLENGE (CAC) MODEL OF ALLERGIC CONJUNCTIVITIS
Munoz, M.
Williams, J. I.
Gow, J. A.
Schooley, G. L.
McNamara, T. R.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A113 - A113
[30] A single-center, double masked, randomized, placebo controlled study to evaluate the efficacy of multiple doses of 10 mg montelukast sodium (Singulair®) on the signs and symptoms of allergic conjunctivitis using the conjunctival allergen challenge (CAC) model
Gomes, P. J.
Abelson, M. B.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S60 - S60

← 1 2 3 →